Prädictive and prognostic biomarkers
Through the application of the longitudinal immune monitoring and the biobanking in numerous clinical trials, a tremendous amount of biological data on the immune status of patients is generated. In order to create predictive and prognostic biomarkers from such biological data sets, it is necessary to include as well data sets on the clinical characteristics of the patients, as well as data on the survival, the therapeutic response or on side effects.
Very often simple statistical methods are not adequate to analyze this vast amount of data, even though a first impression of the data might be generated. In order to unravel broader correlations and connections in these data sets, we aim to apply AI-based methods and data mining approaches in cooperation projects. Thereby, we will determine predictive and prognostic immune signatures from the patients’ individual immune status.
Such predictive and prognostic biomarkers may be applied in the clinic in the future, in order to improve the patient’s therapy, to detect side effects or to even prolong the patient’s life.
Within the scope of these projects and studies, the habilitation of Dr. Anna Donaubauer is aspired.
Dr. rer. nat. Anna-Jasmina Donaubauer
Group lead
PD Dr.-Ing. Dr. habil. med. Benjamin Frey M. Sc.
Stellvertretender Leiter Translationale Strahlenbiologie
E-mail: benjamin.frey(at)uk-erlangen.de
Selected Publications
Scheer I, Becker I, Schmitter C, Semrau S, Fietkau R, Gaipl US, Frey B, Donaubauer AJ Prospective Evaluation of CD45RA+/CCR7- Effector Memory T (TEMRA) Cell Subsets in Patients with Primary and Secondary Brain Tumors during Radiotherapy of the Brain within the Scope of the Prospective Glio-CMV-01 Clinical Trial Cells 02/2023, 12(4):516 DOI: 10.3390/cells12040516
Donaubauer AJ, Becker I, Weissmann T, Fröhlich BM, Munoz LE, Gryc T, Denzler M, Ott OJ, Fietkau R, Gaipl US, Frey B Low Dose Radiation Therapy Induces Long-Lasting Reduction of Pain and Immune Modulations in the Peripheral Blood - Interim Analysis of the IMMO-LDRT01 Trial Frontiers in Immunology 10/2021, 12:740742 DOI: 10.3389/fimmu.2021.740742
Zhou JG* & Donaubauer AJ*, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, Ma H, Schubert P, Schweizer C, Fietkau R, Deutsch E, Gaipl U, Hecht M Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors Journal for Immunotherapy of Cancer 02/2021, 9(2):e001845 DOI: 10.1136/jitc-2020-001845 *contributed equally as first authors
Donaubauer AJ, Deloch L, Becker I, Fietkau R, Frey B, Gaipl US The Influence of Radiation on Bone and Bone Cells-Differential Effects on Osteoclasts and Osteoblasts International Journal of Molecular Science 09/2020, 21(17):6377 DOI: 10.3390/ijms21176377
Donaubauer AJ, Zhou JG, Ott OJ, Putz F, Fietkau R, Keilholz L, Gaipl US, Frey B, Weissmann T Low Dose Radiation Therapy, Particularly with 0.5 Gy, Improves Pain in Degenerative Joint Disease of the Fingers: Results of a Retrospective Analysis International Journal of Molecular Science 08/2020, 21(16):5854 DOI: 10.3390/ijms21165854
Further publications of Dr. Anna-Jasmina Donaubauer available on "web of science reseracher ID"